Health Care [ 7/12 ] | Biotechnology [ 27/75 ]
NASDAQ | Common Stock
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.
It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline BiologicalsS. A.
Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 19, 26 | 0.00 Increased by +100.00% | -0.54 Increased by +100.00% |
| Nov 5, 25 | -1.17 Increased by +25.00% | -0.84 Decreased by -39.29% |
| Jul 30, 25 | -0.80 Increased by +21.57% | -0.78 Decreased by -3.17% |
| Apr 30, 25 | -0.88 Decreased by -83.33% | -0.84 Decreased by -4.35% |
| Feb 20, 25 | -0.76 Increased by +11.63% | -0.89 Increased by +14.61% |
| Oct 31, 24 | -1.56 Decreased by -27.87% | -1.05 Decreased by -48.57% |
| Aug 1, 24 | -1.02 Increased by +29.66% | -0.90 Decreased by -13.33% |
| May 2, 24 | -0.48 Increased by +54.72% | -1.05 Increased by +54.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 240.00 K Decreased by -89.92% | -163.14 M Increased by +23.66% | Decreased by -67.98 K% Decreased by -656.99% |
| Jun 30, 25 | 1.21 M Decreased by -60.52% | -110.96 M Increased by +19.82% | Decreased by -9.14 K% Decreased by -103.10% |
| Mar 31, 25 | 3.03 M Decreased by -94.62% | -120.97 M Decreased by -85.31% | Decreased by -3.99 K% Decreased by -3.35 K% |
| Dec 31, 24 | 12.37 M Decreased by -26.29% | -104.59 M Increased by +9.82% | Decreased by -845.23% Decreased by -22.35% |
| Sep 30, 24 | 2.38 M Decreased by -9.81% | -213.72 M Decreased by -30.78% | Decreased by -8.98 K% Decreased by -45.02% |
| Jun 30, 24 | 3.08 M Decreased by -19.02% | -138.38 M Increased by +28.95% | Decreased by -4.50 K% Increased by +12.27% |
| Mar 31, 24 | 56.38 M Decreased by -10.45% | -65.28 M Increased by +53.67% | Decreased by -115.79% Increased by +48.26% |
| Dec 31, 23 | 16.79 M Decreased by -66.03% | -115.97 M Decreased by -14.14% | Decreased by -690.85% Decreased by -235.96% |